Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
FABm007-06 | Mouse | PerCP-Cy5.5 Labeled Monoclonal Anti-Human CD45 Antibody, Mouse IgG2a |
|
||
CD5-H82E8 | Human | Biotinylated Human CD45 / PTPRC Protein, His,Avitag™ |
|
||
CD5-H5259 | Human | Human CD45 / PTPRC Protein, Llama IgG2b Fc Tag, low endotoxin |
|
||
CD5-H52H8 | Human | Human CD45 / PTPRC protein, His Tag |
|
||
CD5-H82E7 | Human | Biotinylated Human CD45 / PTPRC protein, His,Avitag™ (MALS verified) |
|
|
Flow cytometric analysis of Human peripheral blood lymphocytes respectively staining with PerCP-CY5.5-Labeled Anti-Human CD45 Antibody, mouse IgG2a (AIRFS225-240625F1-Bulk) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with isotype control antibody. PerCP-CY5.5 signal was used to evaluate the binding activity (QC tested).
Loaded Biotinylated Human CD45, His,Avitag (Cat. No. CD5-H82E7) on SA Biosensor, can bind Human Galectin-1, Tag Free (Cat. No. GA1-H4113) with an affinity constant of 2.0 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
The purity of Biotinylated Human CD45, His,Avitag (Cat. No. CD5-H82E7) is more than 85% and the molecular weight of this protein is around 180-210 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Endomyocardial Fibrosis; Cardiomyopathies | Details | |
I-131-Apamistamab | 131IBC8; BC8-I-131; BC-8 | Phase 3 Clinical | Fred Hutchinson Cancer Research Center | Leukemia, Myeloid, Acute; Sezary Syndrome; Neoplasms, Gonadal Tissue; Waldenstrom Macroglobulinemia; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Intraocular Lymphoma; Lymphoma, T-Cell; Pancytopenia; Lymphoma, T-Cell, Cutaneous; Anemia, Sideroblastic; Lymphoma, Large-Cell, Anaplastic; Leukemia, T-Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Hematopoietic stem cell transplantation (HSCT); Leukemia; Neoplastic Cells, Circulating; Leukemia, Hairy Cell; Anemia, Refractory, with Excess of Blasts; Hodgkin Disease; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Lymphomatoid Granulomatosis; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell | Details |
At 211 MAb BC8-B10 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Neoplasms | Details | |
Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Endomyocardial Fibrosis; Cardiomyopathies | Details | |
I-131-Apamistamab | 131IBC8; BC8-I-131; BC-8 | Phase 3 Clinical | Fred Hutchinson Cancer Research Center | Leukemia, Myeloid, Acute; Sezary Syndrome; Neoplasms, Gonadal Tissue; Waldenstrom Macroglobulinemia; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Intraocular Lymphoma; Lymphoma, T-Cell; Pancytopenia; Lymphoma, T-Cell, Cutaneous; Anemia, Sideroblastic; Lymphoma, Large-Cell, Anaplastic; Leukemia, T-Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Hematopoietic stem cell transplantation (HSCT); Leukemia; Neoplastic Cells, Circulating; Leukemia, Hairy Cell; Anemia, Refractory, with Excess of Blasts; Hodgkin Disease; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Lymphomatoid Granulomatosis; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell | Details |
At 211 MAb BC8-B10 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Neoplasms | Details |
This web search service is supported by Google Inc.